the market?
Trius Therapeutics, Inc.
NASDAQ: TSRX
7.95
0.05
(0.63%)
Extended Hours:
$7.57
-$0.38
(-4.78%)
| Today's Open | $7.97 |
|---|---|
| Previous Close | $7.90 |
| Daily Range | $7.81 - $8.05 |
| 52-Week Range | $4.41 - $8.50 |
| Market Cap | $380.6M |
| P/E Ratio | -5.00 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 776,532 |
| Average Daily Volume | 844,416 |
| Current FY EPS | -$1.50 |
How do you think TSRX
will perform against the market?
Top TSRX Bull/Bear Pitches
smolinaroli (0)
Submitted
August 22, 2011
The bullet is. 1)Lead drug in Phase 3 is an improved version of the market leading antibiotic to fight resistant staph infections. Phase 3 data expected early 2012. Two trials underway both receiv … More
zzlangerhans (< 20)
Submitted
May 14, 2011
Trius's share price has now more than doubled from the December lows without a true positive catalyst. The only thing that's new is a very positive write up from Zacks. They make some good points, but … More
News & Commentary
Gains In This Biotech Could Soon Become Infectious to Investors
Valued at less than half of global peak sales estimates, this small biotech, which just reported fantastic phase 3 results, could well be on its way to its first FDA and EU approval.Trius Investors: Hit With Dilution
Unpleasant share dilution for Trius investors.3 Stocks Near 52-Week Lows Worth Buying
Do these fallen angels deserve a second chance? You be the judge!The Worst of 2012: Trius Therapeutics
Trius Therapeutics kicks off our naughty list for the worst health care stocks of 2012.Sector
Healthcare
Industry
Healthcare Information Services
Trius Therapeutics, Inc. (TSRX) Description
Trius Therapeutics is a biopharmaceutical company focused on the discovery development and commercialization of innovative antibiotics for serious life-threatening infections. Website: http://www.triusrx.com/
